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a b s t r a c t 
The COVID-19 outbreak is now one of the most critical 
crises to manage for most of national healthcare systems 
in the world. The situation is complicated by the absence 
of vaccines and authorized pharmacological treatments, ex- 
cept for remdesivir. In this context, many medicaments, in- 
cluding different Ebola and HIV antivirals, are used off-label 
in the hospital wards as life-treating medicines for COVID- 
19 patients. Authorized medicaments manipulation is some- 
times necessary because they are not always formulated to 
be administered to non-cooperative patients or they are in 
shortage. It is this the case of the fixed combination of 
lopinavir/ritonavir, which was extensively used in the first 
phase of the outbreak inducing a shortage of the oral solu- 
tion available in the EU market. This work provides data on 
size distribution, osmolarity other than drug chemical stabil- 
ity of a lopinavir/ritonavir extemporaneous preparation made 
by using the solid dosage form (i.e., tablet) available on the 
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market as drug source. The reported data indicate that such 
preparation is suitable to be delivered through a nasogastric 
tube, and enough stable for two weeks from the preparation 
at room temperature. 
© 2020 The Author(s). Published by Elsevier Inc. 
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d  pecifications Table 
Subject Pharmacology, Toxicology and Pharmaceutical Science 
Specific subject area Pharmaceutical Science 
Type of data Table, Figure, Text 
How data were acquired High-pressure liquid chromatography (HPLC) 
Data format Raw and analyzed 
Parameters for data 
collection 
Data on lopinavir/ritonavir stability in suspension through two-weeks days from the 
preparation after storage at 4 ° and room temperature 
Description of data 
collection 
The pH 4.2-buffered suspension was prepared in a hospital pharmacy by manipulating 
the lopinavir/ritonavir tablet. It was characterized in terms of particle size distribution, 
osmolarity and 15-day chemical stability. The drug stability in suspensions was tested 
at different storage conditions (4 °C, RT) for two weeks. 
Data source location Milan, Italy 
Data accessibility Analyzed data with the article. 
Raw data and chromatograms and preparation procedure with supplementary 
materials. 
alue of the Data 
• The data can be useful to healthcare professionals that need to manipulate lopinavir/ritonavir
fixed combination for treating adults or children affected by COVID-19 or HIV. 
• The data are useful for the development of new dosage forms indicated for inpatients of
intensive care units. 
• The data provide evidence on the physical stability of lopinavir/ritonavir suspended in a pH
4.2-buffered viscous vehicle. 
• The data provide evidence on the lopinavir/ritonavir chemical stability when they are sus-
pended and stored for two weeks at different conditions. 
. Data Description 
One of the possible pharmacological treatments has been investigated in the early stage of
OVID-19 outbreak in the EU resides in the administration of antiretroviral medicaments [ 1 , 2 ].
n particular, the fixed combination of lopinavir, a second-generation antiretroviral that inhibits
iral HIV protease, and ritonavir, an antiviral administered at a low dose as pharmacoenhancer
or lopinavir, (LPV/r) had been considered a possible treatment option for COVID-19 infections,
ased on demonstrated efficacy against SARS-CoV [3] and some anecdotal cases [4] . This fixed
ombination is available in the EU market as an oral solution, soft capsules, and tablets [5] . Both
ral solutions and tablets are generally available in hospitals. The former, designed for pediatric
atients, is also preferred for inpatients since it can be easily administered with the enteral nu-
rition by nasogastric tube. Nevertheless, some criticisms limit the use of the oral solution in
atients fed with enteral nutrition: it contains, as excipient, alcohol that is not indicated in the
ase of nasogastric administration; it is in shortage for the increased demand of the hospitals
ue to the use in intensive care units. Therefore, the unique possibility for ensuring the continu-
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Fig. 1. Exemplification of the particle size distribution of suspension. Panel A: immediately after preparation (blue) and 
after 30 min (green), 60 min (red) and 180 min of rest in the syringe (yellow); panel B: immediately after preparation 
(blue), after 180 min of rest (red) and after manual handshaking (green). (For interpretation of the references to color in 

























ity of patient care resides in the use of solid dosage forms, which must be manipulated by the
hospital pharmacist to allow their enteral administration by nasogastric tube [6] . 
However, the manipulation of industrial drug products may alter the medicine quality profile,
with potential impact on the efficacy and safety of the pharmacological treatment [7] . For exam-
ple, the bioavailability of LPV/r fixed combination can be altered by splitting or crushing of solid
dosage forms [8] . The administration of suspension via nasogastric tube may also be affected by
clogging due to the aggregation of particles of the grounded tablets [9] . Finally, the osmolarity
of administered suspension can influence the bioavailability of drug substances characterized by
a low water solubility or/and permeability (BCS Class III or IV compounds according to the bio-
pharmaceutics classification system), such as LPV/r [10] . Indeed, the enteral administration of a
hypertonic solution may change the drug solubility in the digestive tract in adults. 
This work provides data on the main critical quality attributes of the lopinavir/ritonavir sus-
pension (e.g., size distribution, osmolarity other than drug chemical stability) to support the
establishment of a standardized manipulation procedure at the bedside based on the real-world
experience of Italian hospital pharmacists. In the case of study, a citrate buffer pH 4.2 with 1%
carboxymethyl cellulose (CMC) solution was used as vehicle. 
The preparation according to the procedure reported in Supplementary Materials led to a ho-
mogeneous whiteish suspension characterized by a very fine particulate. Data reported in the
Supplementary Materials show that, after preparation, most of the solid particulate in suspension
resulted in a size lower than 3 μm (d 95 < 3.05) with a median value (d 50 ) of about 0.88 μm. The
suspension remained homogeneous in appearance up to 30 min of rest. Accordingly, the particle
size distribution of the grounded powder did not change significantly, as shown in Fig. 1 . 
Afterwards, the particulate started to aggregate as it can be noted by progressive shift of
the curves towards larger dimensions ( Fig. 1 A) and the increase of the d 50 -value ( Supplemen-
tary Materials ). This finding was not an issue for the clotting of the nasogastric tube during
the administration since the greater particles remain in the range of few micrometres (d 99 <
10 μm; Supplementary Materials ). Still, the aggregation could affect dissolution of the drugs in
the gastrointestinal tract. However, data reported in Fig. 1 B show that manual handshaking of
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Table 1 
Assay of the extemporaneous antiretroviral suspension during stability study at room temperature (RT) and 4 °C. 
Assay (%) 
Sampling time (days) 
0 1 4 15 
At RT 
• Lopinavir 100.0 ± 6.0 129.6 ± 6.9 113.8 ± 6.3 114.5 ± 17.9 
• Ritonavir 100.0 ± 5.6 137.9 ± 7.7 113.2 ± 5.9 115.3 ± 14.3 
At 4 °C 
• Lopinavir 100.0 ± 6.0 90.8 ± 5.1 110.5 ± 2.3 68.5 ± 3.3 





































he suspension for around 1 min was enough to resuspend the precipitate, restoring the initial
article distribution (d 50 = 1.00 μm; Supplementary Materials ). 
The osmolality of the suspension was 322 ± 14 mOsm/Kg, which fell in the range of isotonic-
ty and, therefore, was compatible with the oral administration. Indeed, if the osmolality of the
leum is generally hypotonic in a fasted state ( ≈ 200 mOsm/Kg), it can physiologically tolerate
alues up to 30 0–40 0 mOsm/Kg in fed conditions [11] . Still, the suspension osmolality can in-
rease the water amount retained in the different gastrointestinal sections [8] , reducing the risk
f LPV/r precipitation in the lumen. However, it is also possible that this phenomenon affect
rug permeation and, therefore, bioavailability as observed in children [10] . 
Finally, the chemical stability of extemporaneous antiretroviral suspension was investigated
hrough 15 days. The literature suggests that both drug substances are stable, although lopinavir
eems more stable than ritonavir [12] . On the contrary, few data are available on their stability
n suspension. Table 1 provides data to support the stability of both active substances at the
wo storage conditions. Despite stress conditions applied (acid/basic and heat treatment) on the
uspension, no impurities due to chemical degradation were observed throughout the stability
tudy. However, high variability of the drug assay ( > 15%) was found ( Table 1 ). These findings
ay be probably due to issues in sampling a uniform dose due to sedimentation and viscos-
ty, and this appears more relevant in samples stored at low temperature. Low temperature is
heoretically expected to reduce solubility of the drugs, as well as capability of the aqueous
edium to solvate the particles, obtaining a homogenous suspension. Consequently, the suspen-
ion should be extemporaneously compounded as single-dose preparation and not as multi-dose
nes, particularly if stored at low temperature. 
Overall data suggest that the suspension is enough stable to be delivered through the naso-
astric tube, and it can be pre-made and stored, until use, for two weeks from the preparation
n the hospital pharmacy at room temperature. However, data suggest that single-dose prepara-
ions should be preferred instead of multi-dose preparations to reduce the risk of dosing errors.
. Experimental Design, Materials, and Methods 
.1. Materials 
Kaletra® Tablet 200 mg/50 mg (Abbvie Deutschland GMBH & Co, D). Tablet contents:
opovidone, sorbitan laurate, colloidal anhydrous silica, sodium stearyl fumarate. Film-coating:
ypromellose, titanium dioxide, macrogols type 400 (Polyethylene glycol 400), hydroxypropyl
ellulose, talc, colloidal anhydrous silica, macrogols type 3350 (Polyethylene glycol 3350), yellow
erric oxide E172, polysorbate 80 [5] . 
Sodium carboxymethyl cellulose (CMC), trisodium citrate dihydrate, and citric acid were pur-
hased by Farmalabor (I). All other chemicals/solvents used in the study were analytical gradend they were used without further purification. 































2.2. Suspension preparation 
The exact preparation procedure is reported in Supplementary Materials . Briefly, tablets of
Kaletra® were crushed in a mortar to obtain a fine and homogenous powder. Then, the powder
was precisely weighed and loaded in a 50-ml syringe. Using a female-female Luer-lock connec-
tor, the syringe was linked to another one containing 20-mL of the suspension vehicle. A 1%
w/v CMC solution in pH 4.2 citrate buffer was used as vehicle. The vehicle volume was set up
to obtain a final suspension containing 20 mg/ml of lopinavir and 5 mg/ml of ritonavir. Moving
the syringe pluggers, the powder and the solution had mixed each other to reach a homogenous
whiteish suspension (appx. 50 syringe complete movements). 
2.3. Size distribution analysis 
The size distribution of the solid residues in the compounded antiretroviral preparation was
analyzed by the single-particle optical sensing (SPOS) technique, using an Accusizer 770 (PSS
Inc., USA). In brief, 100 μL of the compounded antiretroviral preparation was analyzed. The area-
weighted cumulative distributions were described as the median and the dispersion of the size
distribution [Span, Eq. (1) ]. 
Span = d 90 − d 10 
d 50 
(1) 
where d 10 , d 50 and d 90 represent the diameters at 10, 50 and 90% of the size area distribution,
respectively. The analyses were carried out at different times from the preparation, i.e. 30, 90,
180 min. For 180 min, the studies were carried out on samples left to rest or shaken by hand.
The data were expressed as the value obtained by a single formulation batch. 
2.4. Osmolarity determination 
The osmolarity of the extemporaneous antiretroviral suspension was tested by using a K-
7400S Semi-Micro Osmometer (Knauer, D). Briefly, a 150-μl aliquot of the extemporaneous an-
tiretroviral suspension was withdrawn and analyzed. The data were expressed as mean ± st.dev.
of three replicas. 
2.5. Stability study 
The suspension stability was tested at 4 °C and room temperature (RT) up to 15 days: fixed
sampling timings were 0, 1, 4, and 15 days. Aliquots of the suspension were stored at both 4 °C
and RT in 1.5 ml polypropylene tube. The sampling was carried out based on volume measure-
ment to simulate sampling conditions in the real-life setting of an intensive care unit (from
bottles to infusion pumps for instance). The aliquots of each suspension were heated to RT and
mixed by a vortex at the time of each analysis. The samples were diluted 1:1 with acetoni-
trile/water 40/60 v/v, mixed by vortex strongly, then sonicated for 10 min. The sample (diluted
1:1) was divided into three replicates diluted 1:125 again with a mixture of acetonitrile/water
40/60 v/v. The obtained dilutions were sonicated for 10 min and shacked by mechanical agita-
tor for 30 min until the analysis in HPLC. Preliminary stress tests were performed on aliquots of
the obtained diluted suspensions to identified degradation compounds of both drugs. Aliquots
of both suspensions were treated in the following conditions: at 96 °C, at RT and 96 °C after the
addition of phosphoric acid (pH 2.5), at RT and 96 °C after the addition of ammonia (pH 10). The
assay of both drugs in the preparation was calculated as Eq. (2) . 
[ Drug assay , % ] t = 
[ A ] t 
[ A ] 0 
x100 (2) 






































Where t is the sampling point (0, 1, 4, 15 days), A t and A 0 are the area HPLC peaks of the
rugs analyzed ad the sampling point t and at the time of the preparation, respectively. Data
ere expressed as mean ± st.dev. of three replicas. 
.6. Analytical method 
A liquid chromatographer Waters 2695 HPLC system (Milan, Italy) coupled with a 2998 PDA
etector was employed. HPLC-PDA system was controlled by Empower 2 Pro-software (version
ear 2005; Waters), based on a validated method previously reported [13] . A Luna® 5 m C18
150 × 4.6 mm ID; Phenomenex, CA) chromatographic column, protected by a SecurityGuard®
ith C18 (4.0 × 3.0 mm ID; Phenomenex, CA) was used for chromatographic separation. Temper-
ture Control Module II (Waters) was set at 45 °C. Runtime was 28 min, performed at 1 mL/min;
obile phase was composed of solvent A (KH 2 PO 4 50 mM with orthophosphoric acid, pH = 3.23)
nd solvent B (acetonitrile). Lopinavir (LPV) and Ritonavir (RTV) were monitored at 260 nm and
41 nm, respectively ( Supplementary Materials ). The chromatographic gradient used was the same
s reported by Zanon and coworkers [2] . Raw data and chromatograms are reported in Supple-
entary Materials . 
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